[The role of angiogenic factors in preeclampsia].
Preeclampsia is one of the most common and most serious complications of pregnancy and the management of this condition still challenges obstetricians. Despite intensive research the etiology of preeclampsia still remains unclear. At the beginning of the 2000s preeclampsia-related research was directed towards factors that influence angiogenesis. Most studies have been carried out on the placental growth factor and soluble fms-like tyrosine kinase-1. Most publications confirm the increased concentrations of antiangiogenic factors and decreased concentrations of proangiogenic factors in maternal blood samples in preeclampsia even before the onset of clinical symptoms. According to our current knowledge antiangiogenic proteins are responsible for the endothelial dysfunction in the symptomatic stage of the disease. Placental growth factor and soluble fms-like tyrosine kinase-1 may have important roles in the prediction and treatment of the disease. The point of care detection of placental growth factor and soluble fms-like tyrosine kinase-1 may be used to predict preeclampsia. Rapid tests are available to determine the serum levels of the two proteins. Removal of soluble fms-like tyrosine kinase-1 from maternal circulation is a potential treatment option for early onset preeclampsia.
Semmelweis Egyetem, Általános Orvostudományi Kar I. Szülészeti és Nőgyógyászati Klinika Budapest Baross u. 27. 1082.
Bálint
B
Alasztics
Semmelweis Egyetem, Általános Orvostudományi Kar I. Szülészeti és Nőgyógyászati Klinika Budapest Baross u. 27. 1082.
Nóra
N
Gullai
Semmelweis Egyetem, Általános Orvostudományi Kar I. Szülészeti és Nőgyógyászati Klinika Budapest Baross u. 27. 1082.
Attila
A
Molvarec
Semmelweis Egyetem, Általános Orvostudományi Kar I. Szülészeti és Nőgyógyászati Klinika Budapest Baross u. 27. 1082.
János
J
Rigó
D043925:Angiogenesis Inducing Agents / Q000097:blood* / Q000378:metabolism; D020533:Angiogenesis Inhibitors / Q000097:blood* / Q000378:metabolism; D015415:Biomarkers / Q000097:blood; D004730:Endothelium, Vascular / Q000378:metabolism / Q000503:physiopathology; D005260:Female; D006801:Humans; D010920:Placenta / Q000378:metabolism; D000072483:Placenta Growth Factor; D010956:Plasmapheresis / Q000379:methods; D011225:Pre-Eclampsia / Q000097:blood / Q000378:metabolism* / Q000503:physiopathology; D011247:Pregnancy; D011257:Pregnancy Proteins / Q000009:adverse effects / Q000097:blood*; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000009:adverse effects / Q000097:blood*
D043925:Angiogenesis Inducing Agents; D020533:Angiogenesis Inhibitors; D015415:Biomarkers; C000608036:PGF protein, human; D011257:Pregnancy Proteins; D000072483:Placenta Growth Factor; C501162:FLT1 protein, human; D040281:Vascular Endothelial Growth Factor Receptor-1
angiogenesis; angiogenezis; placenta; placental growth factor; placentáris növekedési faktor; praeeclampsia; preeclampsia